Treatments and drugsBy Mayo Clinic Staff
Your treatment will be focused on controlling the inflammation with medications and resolving any underlying disease that triggered your vasculitis. For your vasculitis, you may go through two treatment phases — stopping the inflammation and preventing relapse (maintenance therapy).
Both phases involve prescription drugs. Which drugs and how long you need to take them depend on the type of vasculitis, the organs involved and how serious your condition is.
Some people have initial success with treatment, then experience flare-ups later. Others may never see their vasculitis completely go away and need ongoing treatment.
Medications used to treat vasculitis include:
Oct. 08, 2014
- Corticosteroids to control inflammation. Your doctor may prescribe a corticosteroid drug, such as prednisone or methylprednisolone (Medrol). These help control inflammation in the affected blood vessels. Side effects of corticosteroids can be severe, especially if you take them for a long time. Possible side effects include weight gain, diabetes and bone thinning (osteoporosis). If a corticosteroid is needed for long-term (maintenance) therapy, you'll likely receive the lowest dose possible.
Medications to affect the immune system. If you don't respond to corticosteroids, your doctor may prescribe cytotoxic or immunosuppressant drugs. These types of drugs kill or decrease the function of immune system cells causing the inflammation. They include azathioprine (Azasan, Imuran), methotrexate (Trexall, Rheumatrex) and cyclophosphamide. Possible side effects of cyclophosphamide include increased risk of cancer, infertility and infection. So even though this drug is effective in controlling inflammation, it isn't always the first choice, especially for long-term therapy.
Rituximab (Rituxan) is a safe and effective option for treating some types of vasculitis. Rituximab has proved to be a good option for maintenance therapy, unless you have had hepatitis B. A side effect of rituximab is an increased risk of reactivating hepatitis B.
- What is vasculitis? National Heart, Lung, and Blood Institute. http://www.nhlbi.nih.gov/health/health-topics/topics/vas/. Accessed July 16, 2014.
- Longo DL, et al. Harrison's Online. 18th ed. New York, N.Y.: The McGraw-Hill Companies; 2012. http://www.accessmedicine.com/resourceTOC.aspx?resourceID=4. Accessed July 16, 2014.
- Gwathmey KG, et al. Vasculitic neuropathies. Lancet Neurology. 2014;13:67.
- Guillevin L. Infections in vasculitis. Best Practice & Research in Clinical Rheumatology. 2013;27:19.
- Merkel PA. Overview of the management of vasculitis in adults. http://www.uptodate.com/home. Accessed July 17, 2014.
- Tarzi R, et al. Small vessel vasculitides. Medicine. 2014;42:138.
- Ferri FF. Ferri's Clinical Advisor 2015: 5 Books in 1. Philadelphia, Pa.: Mosby Elsevier; 2015. https://www.clinicalkey.com. Accessed July 17, 2014.
- Zand L, et al. Treatment of ANCA-associated vasculitis: New therapies and a look at old entities. Advances in Chronic Kidney Disease. 2014;21:182.
- Murphy JG, et al., eds. Mayo Clinic Cardiology: Concise Textbook. 4th ed. New York, N.Y.: Oxford University Press; 2013.
- Pipitone N, et al. Role of imaging in the diagnosis of large and medium‐sized vessel vasculitis. Rheumatic Disease Clinics of North America. 2013;39:593.
- Warrington KJ, et al. A primer on vasculitis. Minnesota Medicine. 2013;96:36.
- Weyand CM, et al. Giant-cell arteritis and polymyalgia rheumatica. New England Journal of Medicine. 2014;371:50.
- Dammacco F, et al. Therapy for hepatitis C virus-related cryoglobulinemic vasculitis. New England Journal of Medicine. 2013;369:1035.
- Grayson PC, et al. New features of disease after diagnosis in 6 forms of systemic vasculitis. Journal of Rheumatology. 2013;40:1905.
- Specks U, et al. Efficacy of remission-induction regimens for ANCA-associated vasculitis. New England Journal of Medicine. 2013;369:417.